Published on in Vol 11, No 7 (2022): July

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/34206, first published .
Sodium-Glucose Cotransporter-2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes: Protocol for a Kidney End Points Real-world Study (COMBi-KID Study)

Sodium-Glucose Cotransporter-2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes: Protocol for a Kidney End Points Real-world Study (COMBi-KID Study)

Sodium-Glucose Cotransporter-2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes: Protocol for a Kidney End Points Real-world Study (COMBi-KID Study)

Michael Feher   1 * , MD ;   William Hinton   1 * , MSc ;   Anna Forbes   1 , MBChB ;   Neil Munro   2 * , DPhil ;   Mark Joy   1 , PhD ;   David Wheeler   3 * , MD ;   Simon de Lusignan   1 * , MD

1 Clinical Informatics and Health Outcomes Research Group, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom

2 Clinical Informatics, University of Surrey, Guildford, United Kingdom

3 Department of Renal Medicine, University College London, London, United Kingdom

*these authors contributed equally

Corresponding Author:

  • Michael Feher, MD
  • Clinical Informatics and Health Outcomes Research Group
  • Nuffield Department of Primary Care Health Sciences
  • University of Oxford
  • Eagle House, Walton Well Road
  • Oxford, OX2 6ED
  • United Kingdom
  • Phone: 44 1865 289
  • Email: michael.feher@phc.ox.ac.uk